Related Experiment Video
Updated: Jan 3, 2026
Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes
Published on: February 5, 2021
Mucosal Profiling of Pediatric-Onset Colitis and IBD Reveals Common Pathogenics and Therapeutic Pathways
Bing Huang1, Zhanghua Chen2, Lanlan Geng1
1Department of Gastroenterology, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China.
Insights
Pediatric colitis and inflammatory bowel disease (IBD) share common pathways involving cyclic AMP (cAMP) signaling. Targeting these pathways with dipyridamole shows promise for restoring immune balance and improving symptoms in children.
Area of Science:
- Gastroenterology and Immunology
- Pediatric Inflammatory Bowel Disease Research
- Single-cell Omics and Immune Profiling
Background:
- Pediatric-onset colitis and inflammatory bowel disease (IBD) significantly impact child growth.
- The precise etiopathogenesis of different pediatric IBD subtypes is not fully understood.
- Identifying common and distinct disease mechanisms is crucial for effective treatment.
Purpose of the Study:
- To investigate the molecular and cellular underpinnings of pediatric undifferentiated colitis, Crohn's disease, and ulcerative colitis.
- To identify shared and disease-specific pathogenic pathways in pediatric colitis and IBD.
- To explore potential therapeutic targets for these conditions.
Main Methods:
- Single-cell clustering and immune phenotyping of colonic tissue from children.
- Analysis of genetic risk factors associated with pediatric colitis and IBD.
- Assessment of cyclic AMP (cAMP)-response signaling pathways.
- Pilot study using a phosphodiesterase inhibitor (dipyridamole) to target identified pathways.
Main Results:
- Demonstrated disease-specific characteristics alongside common pathogenesis in pediatric colitis and IBD.
- Identified impaired cyclic AMP (cAMP)-response signaling as a common feature.
- Observed infiltration of PDE4B- and TNF-expressing macrophages, decreased CD39+ intraepithelial T cells, and platelet activation (5-hydroxytryptamine release) in affected children.
- Pilot treatment with dipyridamole restored immune homeostasis and improved colitis symptoms.
Conclusions:
- Comprehensive analysis of colonic mucosa reveals common pathogenic mechanisms in pediatric colitis and IBD.
- Impaired cAMP signaling, specific immune cell infiltrates, and platelet activation represent key shared pathways.
- Targeting these pathways, such as with phosphodiesterase inhibitors, offers a promising therapeutic strategy for pediatric IBD.
Abstract:
Pediatric-onset colitis and inflammatory bowel disease (IBD) have significant effects on the growth of infants and children, but the etiopathogenesis underlying disease subtypes remains incompletely understood. Here, we report single-cell clustering, immune phenotyping, and risk gene analysis for children with undifferentiated colitis, Crohn's disease, and ulcerative colitis. We demonstrate disease-specific characteristics, as well as common pathogenesis marked by impaired cyclic AMP (cAMP)-response signaling. Specifically, infiltration of PDE4B- and TNF-expressing macrophages, decreased abundance of CD39-expressing intraepithelial T cells, and platelet aggregation and release of 5-hydroxytryptamine at the colonic mucosae were common in colitis and IBD patients. Targeting these pathways by using the phosphodiesterase inhibitor dipyridamole restored immune homeostasis and improved colitis symptoms in a pilot study. In summary, comprehensive analysis of the colonic mucosae has uncovered common pathogenesis and therapeutic targets for children with colitis and IBD.
More Related Videos
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
06:57Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
Published on: September 18, 2016
Related Concept Videos
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...